Mycamine (Micafungin)

Micafungin is used to treat fungal infections caused by Candida species, acting on systemic and mucosal disease.

• Invasive candidiasis: effective treatment of systemic Candida infection in adult and pediatric patients.
• Candidemia: eradication of bloodstream Candida infection to reduce mortality.
• Esophageal candidiasis: resolution of mucosal lesions and symptom relief in immunocompromised individuals.
• Prophylaxis in hematopoietic stem cell transplant patients: prevention of invasive Candida infections during the high‑risk post‑transplant period.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesis of β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and cell lysis, while having minimal effect on human cells that lack this polymer. The selective inhibition results in fungicidal activity against most Candida species and limited activity against Aspergillus.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever
• Nausea
• Headache
• Infusion‑related reactions (flushing, chills)

Serious or Rare Side Effects

• Hepatic failure
• Severe hypersensitivity including anaphylaxis
• Acute renal impairment
• Stevens‑Johnson syndrome/toxic epidermal necrolysis

Precautions should be observed when using Micafungin to minimize risks and ensure safe therapy.

• Renal function monitoring: assess serum creatinine before and during treatment.
• Hepatic function monitoring: check liver enzymes regularly.
• Known hypersensitivity: avoid use in patients with previous allergic reactions to micafungin or other echinocandins.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Concomitant hepatotoxic drugs: monitor for additive liver toxicity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medications, affecting its concentration or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure.
• Co‑administration with other echinocandins: increased risk of additive toxicity.
• Concurrent use with known hypersensitivity agents: heightened risk of severe allergic reactions.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin plasma levels.
• Cyclosporine or tacrolimus: potential for increased immunosuppressant concentrations.
• Warfarin: monitor INR as micafungin may affect anticoagulant effect.